Developing novel anti-cancer agens by high throughput chemical screens for small molcules that modulate the pro-survival [ 2004 - 2004 ]

Also known as: Bcl-2 inhibitors as anti-cancer drugs

Research Grant

[Cite as]

Researchers: Prof David Huang (Principal investigator) ,  A/Pr Ian Street A/Pr Mark Hinds Dr Keith Watson Prof Jerry Adams
View all 7 related researchers

Brief description Cancer is the second commonest cause of deaths in our community. Unfortunately, treatment often fails or causes unwanted side effects. This proposal seeks to discover and develop a novel class of anti-cancer drugs that act by directly activating programmed cell death (apoptosis). The Bcl-2 proteins are key regulators of cell death and by exploiting knowledge about these prime targets for cancer therapy, we aim to discover drugs that are potentially of considerable medical and commercial value.

Funding Amount $AUD 125,000.00

Funding Scheme NHMRC Development Grants

Notes Development Grant

Click to explore relationships graph
Viewed: [[ro.stat.viewed]]